Difference between revisions of "Fotemustine (Muphoran)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "Category:Drug index" to "Category:Drugs")
m
Line 2: Line 2:
 
From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=38865 NCI Drug Dictionary]: A chloroethylating nitrosourea with antineoplastic activity. Fotemustine alkylates guanine by forming chloroethyl adducts at the 6 position of guanine, resulting in N1-guanine and N3-cytosine cross linkages, inhibition of DNA synthesis, cell cycle arrest, and finally apoptosis. This agent is lipophilic and crosses the blood-brain barrier.
 
From the [http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=38865 NCI Drug Dictionary]: A chloroethylating nitrosourea with antineoplastic activity. Fotemustine alkylates guanine by forming chloroethyl adducts at the 6 position of guanine, resulting in N1-guanine and N3-cytosine cross linkages, inhibition of DNA synthesis, cell cycle arrest, and finally apoptosis. This agent is lipophilic and crosses the blood-brain barrier.
  
−
==Preliminary data==
+
==Diseases for which it is used==
 +
*[[Melanoma]]
  
−
===[[Hodgkin lymphoma]]===
+
==Also known as==
−
# Musso M, Messina G, Di Renzo N, Di Carlo P, Vitolo U, Scalone R, Marcacci G, Scalzulli PR, Moscato T, Matera R, Crescimanno A, Santarone S, Orciuolo E, Merenda A, Pavone V, Pastore D, Donnarumma D, Carella AM, Ciochetto C, Cascavilla N, Mele A, Lanza F, Di Nicola M, Bonizzoni E, Pinto A. Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen. Br J Haematol. 2016 Jan;172(1):111-21. Epub 2015 Oct 12. [https://onlinelibrary.wiley.com/doi/10.1111/bjh.13803/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26458240 PubMed]
+
*'''Brand names:''' Muphoran, Mustophoran
−
 
 
−
===[[Transplant conditioning regimens]]===
 
−
# Musso M, Scalone R, Marcacci G, Lanza F, Di Renzo N, Cascavilla N, Di Bartolomeo P, Crescimanno A, Perrone T, Pinto A. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant. 2010 Jul;45(7):1147-53. Epub 2009 Nov 9. [https://www.nature.com/bmt/journal/v45/n7/full/bmt2009318a.html link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19898504 PubMed]
 
  
 
[[Category:Drugs]]
 
[[Category:Drugs]]
−
[[Category:Chemotherapy]]
 
 
[[Category:Intravenous medications]]
 
[[Category:Intravenous medications]]
 
[[Category:Nitrosoureas]]
 
[[Category:Nitrosoureas]]
  
−
[[Category:Hodgkin lymphoma medications]]
+
[[Category:Melanoma medications]]
−
[[Category:Transplant medications]]
 
  
−
[[Category:Investigational]]
+
[[Category:EMA approved drugs]]

Revision as of 01:25, 12 August 2018

Mechanism of action

From the NCI Drug Dictionary: A chloroethylating nitrosourea with antineoplastic activity. Fotemustine alkylates guanine by forming chloroethyl adducts at the 6 position of guanine, resulting in N1-guanine and N3-cytosine cross linkages, inhibition of DNA synthesis, cell cycle arrest, and finally apoptosis. This agent is lipophilic and crosses the blood-brain barrier.

Diseases for which it is used

Also known as

  • Brand names: Muphoran, Mustophoran
Retrieved from "https://hemonc.org/w/index.php?title=Fotemustine_(Muphoran)&oldid=29877"